| Filed On | Filing |
|---|---|
| 30 Oct 2026 |
8-K: Results of Operations and Financial Condition
Tarrytown, New York (October 30, 2026) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update. |
| 06 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron” or the “Company”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“Sanofi Biotechnology”), and Sanofi... |
| 30 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Plan: Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
Tarrytown, New York (July 30, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update. |
| 06 Jul 2026 |
8-K: Results of Operations and Financial Condition
Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the s... |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2026 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) held on June 12, 2026, Regeneron’s shareholders voted on the matters set forth below. |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition
Tarrytown, New York (April 29, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update. |
| 08 Apr 2026 |
8-K: Results of Operations and Financial Condition
Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the f... |
| 30 Jan 2026 |
8-K: Results of Operations and Financial Condition
Tarrytown, New York (January 30, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business update. |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
J a n u a r y 1 2 , 2 0 2 6 J.P. Morgan Healthcare Conference This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. |
| 28 Oct 2025 |
8-K: Results of Operations and Financial Condition
Tarrytown, New York (October 28, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update. |
| 06 Oct 2025 |
8-K: Results of Operations and Financial Condition
Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the t... |
| 01 Aug 2025 |
8-K: Results of Operations and Financial Condition
Tarrytown, New York (August 1, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update. |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2025 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) held on June 13, 2025, Regeneron’s shareholders voted on the matters set forth below. |
| 29 Apr 2025 |
8-K: Results of Operations and Financial Condition
Tarrytown, New York (April 29, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update. |
| 04 Feb 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference |
| 31 Oct 2024 |
8-K: Results of Operations and Financial Condition
Tarrytown, New York (October 31, 2024) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. |
| 07 Oct 2024 |
8-K: Results of Operations and Financial Condition
Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the t... |
| 01 Aug 2024 |
8-K: Results of Operations and Financial Condition
Tarrytown, New York (August 1, 2024) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2024 and provided a business update. |
Loading...